Yttrium (90Y) tacatuzumab tetraxetan is an investigational humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | α-fetoprotein |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6470H9971N1712O2007S4290Y |
| Molar mass | 145 kg/mol |
  (what is this?) (verify) | |
References
edit- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council". 4 September 2004. Archived from the original on 2004-09-11.
- ^ WHO Drug Information
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 | This nuclear medicine article is a stub. You can help Wikipedia by expanding it. |